ADIL

ADIAL PHARMACEUTICALS, INC. ADIL

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.0M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Top Institutional Holders

as of Q2 2026
$1.92M total
Stonepine Capital Management, LLC
$1.58MNew
JANE STREET GROUP, LLC
$82.2KNew
CITADEL ADVISORS LLC
$75.6KNew
UBS Group AG
$49.0K+3432.7%
StoneX Group Inc.
$35.7KNew
GEODE CAPITAL MANAGEMENT, LLC
$31.7K-48.9%
China Universal Asset Management Co., Ltd.
$20.5KNew
VANGUARD FIDUCIARY TRUST CO
$15.1K0.0%
VANGUARD CAPITAL MANAGEMENT LLC
$14.9K+1515.2%
Manchester Capital Management LLC
$4.9K0.0%
Tower Research Capital LLC (TRC)
$3.6K+4.6%
BlackRock, Inc.
$778-72.6%
RAFFA WEALTH MANAGEMENT, LLC
$2120.0%
MORGAN STANLEY
$1280.0%
SBI Securities Co., Ltd.
$1200.0%
WELLS FARGO & COMPANY/MN
$150.0%
HARBOUR INVESTMENTS, INC.
$80.0%
Abound Wealth Management
$30.0%
See all 18 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

Q2 2026
EDGAR

EPS (Diluted)

Q2 2026
EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/ADIL

Earnings Per Share

13fpro.ai/company/ADIL

Loading ratio trend…

ADIL insiders

Officers, directors and 10% owners with a Form 4 filed in the last 24 months, most recent first. From SEC EDGAR.

About ADIAL PHARMACEUTICALS, INC. (ADIL): stock profile, AI score and financials

ADIAL PHARMACEUTICALS, INC. (ADIL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. ADIL is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.0m in revenue and is scored on the micro-cap board instead. Top institutional holders of ADIL by reported 13-F value include Stonepine Capital Management, JANE STREET GROUP, CITADEL ADVISORS, based on the most recent SEC filings. ADIL trades on the Nasdaq exchange and files with the SEC under CIK 1513525. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ADIL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ADIAL PHARMACEUTICALS, INC. directly from SEC EDGAR.

Financials through the period ended SEC EDGAR: CIK 1513525 →